Michael E. Trautmann M.D. is an internationally recognized expert for Diabetes treatment and in particular for GLP-1 and insulins. He trained in Internal Medicine and Diabetology at the Universities Goettingen and Marburg, Germany, and Geneva, Switzerland. His clinical research focused on diabetes treatment and endocrine tumors of the gut. In his laboratory intracellular mechanisms involved in controlling insulin release and cell differentiation of pancreatic beta cells were investigated. Already since 1987 he has been involved in research around Glucagon-like peptide-1 and its effects on insulin secretion.In 1993, he joined Lilly Germany as Clinical Research Physician for Diabetes where he was responsible for the clinical development of insulin lispro (Humalog). From 1996 to 1998 he was Global Physician in the Endocrine Therapeutic Area in Indianapolis with responsibilities for early phase development of novel therapeutic approaches in the area of obesity and Type 2 diabetes treatment. Thereafter he moved to the new Lilly Research Laboratories in Hamburg and coordinated early phase clinical programs. He worked on several programs in the area of GLP-1. Under his scientific leadership exenatide (Byetta and Bydureon) was developed and approved for the treatment of Diabetes in Europe, USA, and Japan. He retired from Lilly in 2011 as Senior Medical Fellow in the Lilly Diabetes Global Medical Team and works now as independent consultant for Diabetes drug development and Diabetes research on projects related to Diabetes therapy, particularly development of improved insulin preparations, GLP-1 agonists, gastrointestinal hormones, and new drugs for the treatment of Diabetes and Obesity, as well as innovative devices. Michael Trautmann is member of several national and international associations for Diabetes and Endocrine Research and has authored numerous publications in this field.
Diabetes Forschung Hamburg
Was gibt es Neues unter der Sonne?